SVB Securities Initiates a Buy Rating on Denali Therapeutics (DNLI)

Denali Therapeutics (DNLIResearch Report) received a Buy rating and a $50.00 price target from SVB Securities analyst Marc Goodman today. The company’s shares closed last Friday at $31.47.

According to TipRanks, Goodman is a 4-star analyst with an average return of 2.9% and a 48.08% success rate. Goodman covers the Healthcare sector, focusing on stocks such as Axsome Therapeutics, Marinus, and Biogen.

Denali Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $58.40, an 85.57% upside from current levels. In a report released on January 25, Morgan Stanley also maintained a Buy rating on the stock with a $65.00 price target.

See the top stocks recommended by analysts >>

Based on Denali Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $3.56 million and a GAAP net loss of $103.3 million. In comparison, last year the company earned a revenue of $5.29 million and had a GAAP net loss of $84.59 million

Based on the recent corporate insider activity of 48 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of DNLI in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.

Read More on DNLI:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More